TransIT^®-2020

Fig. 1 | TransIT^®-2020 Reagent Exhibits Higher Expression and Lower Cellular Toxicity Compared to Other Transfection Reagents. Human umbilical vein endothelial cells (HUVEC) were transfected with a luciferase expression plasmid using the designated reagents at the reagent-to-DNA ratios indicated beneath each bar. Transfections were performed in 96-well plates using 0.1 µg of plasmid DNA per well. Luciferase expression (bar graph) and lactate dehydrogenase (LDH) levels (line graph) were measured at 24 hours post-transfection. LDH levels are reported as % cytotoxicity compared to cells alone and were measured using a commercially available colorimetric assay; all values at or below zero are represented as zero on graph. Error bars represent the standard deviation of triplicate wells.

Fig. 2 | High Performance Plasmid Transfection. Primary Human Small Epithelial Cells (HSAEpic) were transfected using TransIT^®-2020 and an EGFP expression plasmid (4:1 reagent-to-DNA ratio). Images were taken 24 hours post-transfection using a Zeiss axiovert inverted fluorescence microscope.

Fig. 3 | Superior Gene Expression in a Broad Spectrum of Cell Types. The indicated cell types were transfected in 96-well plates with a luciferase expression plasmid (0.1 µg/well) according to industry accepted testing protocols. Reagent to DNA ratios were optimized for each cell type: TransIT^®-2020 (Mirus Bio, 2:1 or 3:1), FuGENE^® HD (Roche, 3.5:1), Lipofectamine^® 2000 (Life Technologies, 1.5:1, 3:1 or 5:1). Luciferase activity was measured 24 hours post-transfection. Values were normalized to TransIT^®-2020 and presented as a percentage of luciferase expression. FuGENE^® is a registered trademark of Fugent LLC. Lipofectamine^® is a trademark of Life Technologies Corporation.